Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Bella Pharmaceuticals, Inc.
483
•Bella Pharmaceuticals, Inc.•August 3, 2017

Bella Pharmaceuticals, Inc. – FDA 483, Aug 3, 2017

Record Details

An FDA inspection conducted at Bella Pharmaceuticals, Inc., an outsourcing facility in Chicago, IL, from June 10 to July 18, 2017, revealed significant deviations from regulatory requirements. The FDA Form 483 issued to Owner Michael B. Younan detailed critical observations across various operational areas. Key issues included a lack of validated aseptic filling procedures, insufficient environmental and personnel monitoring for microbiological contamination, and poor sanitization practices within sterile compounding areas. The facility exhibited structural deficiencies, such as a chipping floor in the ISO-5 area and improper seals. The company also failed to maintain adequate production records for compounded sterile drugs and lacked crucial finished product testing, including potency, endotoxin, and sterility suitability. Furthermore, control over bulk drug substances was inadequate, with expired materials available, and personnel gowning procedures were found to be deficient, leading to exposed skin during sterile compounding. Critically, drug product labels were missing mandatory information, such as statements identifying them as compounded drugs, active ingredient lists, compounding dates, and adverse event reporting details, as required for outsourcing facilities. Bella Pharmaceuticals is expected to provide a comprehensive response outlining its corrective and preventive actions to address these serious observations.

Company
Bella Pharmaceuticals, Inc.
Inspection date
August 3, 2017
Product type
Drugs
Office
Division of Information Disclosure Policy
Person
  • Brian D. Nicholson
View Company Profile

ID · 82ae1492-168e-4ec5-bf94-d09204721919

Violation Codes5
21 CFR 21021 CFR 21121 CFR 331(c)21 U.S.C. 503B(a)(10)(A)21 U.S.C. 503B(a)(10)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bella Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.